Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis

Monica Tang, Timothy Jay Price, Jeremy Shapiro, Peter Gibbs, Daniel G. Haller, Dirk Arnold, Marc Peeters, Eva Segelov, Amitesh Roy, Niall Tebbutt, Nick Pavlakis, Chris Karapetis, Matthew Burge

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

Introduction: Oxaliplatin-based adjuvant chemotherapy has been the standard of care for resected early colon cancer for over a decade. Recent results from the IDEA meta-analysis attempt to address the question of whether 3 or 6 months of adjuvant chemotherapy is preferable in Stage III colon cancer. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of adjuvant therapy for resected early colon cancers. This article reviews the current evidence for adjuvant treatment of Stage II and III colon cancer, as well as up-to-date data regarding optimal duration of therapy. This article reviews the evidence for lifestyle modifications in the management of early colorectal cancer and other future directions for research in early colon cancer. Expert commentary: In recent years, there have been no advances in the development of novel agents for adjuvant therapy in colorectal cancer. Although the IDEA meta-analysis was negative for its primary non-inferiority endpoint, the detailed results provide valuable information that allows personalisation of treatment regimen and duration.

Original languageEnglish
Pages (from-to)339-349
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume18
Issue number4
DOIs
Publication statusPublished - 3 Apr 2018

Keywords

  • adjuvant treatment
  • chemotherapy
  • Colon cancer
  • duration of chemotherapy
  • IDEA collaboration

Cite this

Tang, Monica ; Price, Timothy Jay ; Shapiro, Jeremy ; Gibbs, Peter ; Haller, Daniel G. ; Arnold, Dirk ; Peeters, Marc ; Segelov, Eva ; Roy, Amitesh ; Tebbutt, Niall ; Pavlakis, Nick ; Karapetis, Chris ; Burge, Matthew. / Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. In: Expert Review of Anticancer Therapy. 2018 ; Vol. 18, No. 4. pp. 339-349.
@article{fcd712de8a624c26a440956e68a87dbb,
title = "Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis",
abstract = "Introduction: Oxaliplatin-based adjuvant chemotherapy has been the standard of care for resected early colon cancer for over a decade. Recent results from the IDEA meta-analysis attempt to address the question of whether 3 or 6 months of adjuvant chemotherapy is preferable in Stage III colon cancer. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of adjuvant therapy for resected early colon cancers. This article reviews the current evidence for adjuvant treatment of Stage II and III colon cancer, as well as up-to-date data regarding optimal duration of therapy. This article reviews the evidence for lifestyle modifications in the management of early colorectal cancer and other future directions for research in early colon cancer. Expert commentary: In recent years, there have been no advances in the development of novel agents for adjuvant therapy in colorectal cancer. Although the IDEA meta-analysis was negative for its primary non-inferiority endpoint, the detailed results provide valuable information that allows personalisation of treatment regimen and duration.",
keywords = "adjuvant treatment, chemotherapy, Colon cancer, duration of chemotherapy, IDEA collaboration",
author = "Monica Tang and Price, {Timothy Jay} and Jeremy Shapiro and Peter Gibbs and Haller, {Daniel G.} and Dirk Arnold and Marc Peeters and Eva Segelov and Amitesh Roy and Niall Tebbutt and Nick Pavlakis and Chris Karapetis and Matthew Burge",
year = "2018",
month = "4",
day = "3",
doi = "10.1080/14737140.2018.1444481",
language = "English",
volume = "18",
pages = "339--349",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Taylor & Francis",
number = "4",

}

Tang, M, Price, TJ, Shapiro, J, Gibbs, P, Haller, DG, Arnold, D, Peeters, M, Segelov, E, Roy, A, Tebbutt, N, Pavlakis, N, Karapetis, C & Burge, M 2018, 'Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis', Expert Review of Anticancer Therapy, vol. 18, no. 4, pp. 339-349. https://doi.org/10.1080/14737140.2018.1444481

Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. / Tang, Monica; Price, Timothy Jay; Shapiro, Jeremy; Gibbs, Peter; Haller, Daniel G.; Arnold, Dirk; Peeters, Marc; Segelov, Eva; Roy, Amitesh; Tebbutt, Niall; Pavlakis, Nick; Karapetis, Chris; Burge, Matthew.

In: Expert Review of Anticancer Therapy, Vol. 18, No. 4, 03.04.2018, p. 339-349.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis

AU - Tang, Monica

AU - Price, Timothy Jay

AU - Shapiro, Jeremy

AU - Gibbs, Peter

AU - Haller, Daniel G.

AU - Arnold, Dirk

AU - Peeters, Marc

AU - Segelov, Eva

AU - Roy, Amitesh

AU - Tebbutt, Niall

AU - Pavlakis, Nick

AU - Karapetis, Chris

AU - Burge, Matthew

PY - 2018/4/3

Y1 - 2018/4/3

N2 - Introduction: Oxaliplatin-based adjuvant chemotherapy has been the standard of care for resected early colon cancer for over a decade. Recent results from the IDEA meta-analysis attempt to address the question of whether 3 or 6 months of adjuvant chemotherapy is preferable in Stage III colon cancer. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of adjuvant therapy for resected early colon cancers. This article reviews the current evidence for adjuvant treatment of Stage II and III colon cancer, as well as up-to-date data regarding optimal duration of therapy. This article reviews the evidence for lifestyle modifications in the management of early colorectal cancer and other future directions for research in early colon cancer. Expert commentary: In recent years, there have been no advances in the development of novel agents for adjuvant therapy in colorectal cancer. Although the IDEA meta-analysis was negative for its primary non-inferiority endpoint, the detailed results provide valuable information that allows personalisation of treatment regimen and duration.

AB - Introduction: Oxaliplatin-based adjuvant chemotherapy has been the standard of care for resected early colon cancer for over a decade. Recent results from the IDEA meta-analysis attempt to address the question of whether 3 or 6 months of adjuvant chemotherapy is preferable in Stage III colon cancer. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of adjuvant therapy for resected early colon cancers. This article reviews the current evidence for adjuvant treatment of Stage II and III colon cancer, as well as up-to-date data regarding optimal duration of therapy. This article reviews the evidence for lifestyle modifications in the management of early colorectal cancer and other future directions for research in early colon cancer. Expert commentary: In recent years, there have been no advances in the development of novel agents for adjuvant therapy in colorectal cancer. Although the IDEA meta-analysis was negative for its primary non-inferiority endpoint, the detailed results provide valuable information that allows personalisation of treatment regimen and duration.

KW - adjuvant treatment

KW - chemotherapy

KW - Colon cancer

KW - duration of chemotherapy

KW - IDEA collaboration

UR - http://www.scopus.com/inward/record.url?scp=85042912196&partnerID=8YFLogxK

U2 - 10.1080/14737140.2018.1444481

DO - 10.1080/14737140.2018.1444481

M3 - Article

VL - 18

SP - 339

EP - 349

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 4

ER -